Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 87-94

  Bymaster, Frank P ^a   Hemrick Luecke, Susan K ^a   Perry, Kenneth W ^a   Fuller, Ray W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atypical antipsychotic; Dopamine; Dopamine antagonist; Muscarinic; Olanzapine; Serotonin

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; 3 HYDROXYBENZYLHYDRAZINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL SULFATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR; DOPA; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR; GAMMA BUTYROLACTONE; HOMOVANILLIC ACID; KETANSERIN; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NOMIFENSINE; OLANZAPINE; PERGOLIDE; PIRENZEPINE; QUIPAZINE; RADIOLIGAND; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ANTAGONISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; MALE; MONOAMINE METABOLISM; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENERGIC ANTAGONISTS; ANIMALS; BENZODIAZEPINES; BRAIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCARINIC ANTAGONISTS; NUCLEUS ACCUMBENS; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS;

EID: 0029880065     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245608     Document Type: Article

References (47)

1. 2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16: 517-525
2. 3H]SCH23390 binding in vivo. Eur J Pharmacol 120: 143-144
3. Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Holman S and the olanzapine HGAD Study Group (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 14: 111-123
4. Benvenga MJ, Leander JD (1995) Olanzapine increases rates of punished responding in pigeons. Psychopharmacology 119: 133-138
5. Bymaster FP, Heath I, Hendrix JC, Shannon HE (1993) Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267: 16-24
6. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96
7. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607-1619
8. 2 receptors: implications for drug mechanism of action. Life Sci 39: 2571-2580
9. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483
10. Demarest KT, Moore KE (1980) Accumulation of L-dopa in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity. Endocrinology 106: 463-468
11. Fuller RW, Perry KW (1989) Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther 248: 50-56
12. Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Res Comm Chem Pathol Pharmacol 77: 87-93
13. Fuller RW, Snoddy HD, Perry KW (1978) Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart. Arch Int Pharmacodyn Ther 231: 30-41
14. Fuller RW, Clemens JA, Kornfeld ED, Snoddy HD, Smalstig EB, Bach NJ (1979) Effect of (8β)-8-[(methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci 24: 375-382
15. 1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuropsychopharmacol Biol Psychiatry 18: 803-821
16. Heal DJ, Frankland ATJ, Buckett WR (1990) A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection. Studies with drugs which alter dopamine metabolism in the brain. Neuropharmacology 29: 1141-1150
17. Hemrick-Luecke SK, Bymaster FP, Falcone JF, Moore NA, Tye NC, Fuller RW (1993) Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Soc Neurosci Abstr 19: 383
18. Hemrick-Luecke SK, Snoddy HD, Fuller RW (1994) Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 55: 479-483
19. Marchi M, Raiteri M (1985) On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties. J Pharmacol Exp Ther 235: 230-233
20. Martin GE, Williams M, Haubrich DR (1982) A pharmacologic comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists. J Pharmacol Exp Ther 223: 298-304
21. McGeer PL, Grewaal DS, McGeer EG (1974) Influence of noncholinergic drugs on rat striatal acetylcholine levels. Brain Res 80: 211-217
22. McKinney M, Miller JH, Aagaard PJ (1993) Pharmacological characterization of the rat hippocampal autoreceptor. J Pharmacol Exp Ther 264: 74-78
23. McMillen BA, Shore P (1978) Comparative effects of clozapine and α-adrenergic blocking drugs on regional noradrenaline metabolism in rat brain. Eur J Pharmacol 52: 225-230
24. Meek JL, Neff NH (1973) The rate of formation of 3-methoxy-4-hydroxyphenylethyleneglycol sulfate in brain as an estimate of the rate of formation of norepinephrine. J Pharmacol Exp Ther 184: 570-575
25. 2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol Exp Ther 233: 656-662
26. Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246
27. Miller RJ, Hiley CR (1974) Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248: 596-597
28. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262: 545-551
29. Moore NA, Calligaro DO, Wong DT, Bymaster FP, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2: 281-293
30. Moore NA, Rees G, Sanger G, Tye NC (1994) Effect of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5: 196-202
31. 2 receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology (in press)
32. Obermeyer BD, Nyhart EH, Mattiuz EL, Goodwin M, Barton RD, Breau AP, Gillespie TA, Binkley SN, Reubin A, Lemberger L (1993) The disposition of olanzapine in healthy volunteers. Pharmacologist 35: 176
33. Perry KW, Fuller RW (1991) Serotonergic drugs increase MHPG-SO4 in rat hypothalamus. Soc Neurosci Abstr 17: 1178
34. Przegalinski E, Kordecka-Magiera A, Mogilnicka E, Maj J (1981) Chronic treatment with some atypical antidepressants increases the brain level of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rats. Psychopharmacology 74: 187-190
35. Rasmussen K, Aghajanian GK (1988) Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5HT2 binding affinity. Neuropsychopharmacology 1: 101-107
36. Roth RH, Wolf ME, Deutch AY (1987) Neurochemistry of mid-brain dopamine systems. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 81-94
37. Sacaan AI, Bymaster FP, Schoepp DD (1992) Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by dopamine. J Neurochem 59: 245-251
38. Saller CF, Salama AI (1986) 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds. Naunyn-Schmiedeberg's Arch Pharmacol 334: 125-132
39. Seeman P, Lee T, Chang-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-718
40. Sethy VH, Van Woert MH (1973) Antimuscarinic drugs-effect on brain acetylcholine and tremors in rats. Biochem Pharmacol 22: 2685-2691
41. Sethy VH, Van Woert MH (1974) Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Res Comm Chem Pathol Pharmacol 8: 13-28
42. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14: 92-104
43. Umezu K, Moore KE (1979) Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid. J Pharmacol Exp Ther 208: 49-56
44. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614
45. Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: similar biochemical and histochemieal effects of γ-hydroxy-butyrate and acute lesions of the nigro-neostriatal pathway. J Pharmacol Exp Ther 186: 630-639
46. Westerink BHC (1985) Sequence and significance of dopamine metabolism in the rat brain. Neurochem Int 7: 221-227
47. Zetterstrom T, Sharp T, Ungerstedt U (1985) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106:27-37